6 research outputs found
Ethical Appraisal of Credit-Card Marketing Strategy:Measure and Antecedent Exploration of Consumer Vulnerability to Credit-Card Debt
The dose response data for cotinine across the 10 EOC cell lines. (PNG 1793 kb
Additional file 9: Figure S9. of Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
The dose response data for doxorubicin across the 10 EOC cell lines. (PNG 2018 kb
Additional file 2: Figure S2. of Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
Results from clustering tumors from the TCGA and Mayo Clinic studies. Analyses were completed with genes found to be associated with clinical outcome in both studies (adjustment for clinical covariates). (PNG 1017 kb
Additional file 11: Figure S11. of Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
The dose response data for mitoxantrone across the 10 EOC cell lines. (PNG 2056 kb
Additional file 14: Table S1. of Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
DGE and CMAP results. (XLSX 489 kb
Assessing Breast Cancer Molecular Subtypes Using Extracellular Vesicles’ mRNA
Extracellular vesicles (EVs) carry
RNA cargo that is
believed to
be associated with the cell-of-origin and thus have the potential
to serve as a minimally invasive liquid biopsy marker for supplying
molecular information to guide treatment decisions (i.e., precision
medicine). We report the affinity isolation of EV subpopulations with
monoclonal antibodies attached to the surface of a microfluidic chip
that is made from a plastic to allow for high-scale production. The
EV microfluidic affinity purification (EV-MAP) chip was used for the
isolation of EVs sourced from two-orthogonal cell types and was demonstrated
for its utility in a proof-of-concept application to provide molecular
subtyping information for breast cancer patients. The orthogonal selection
process better recapitulated the epithelial tumor microenvironment
by isolating two subpopulations of EVs: EVEpCAM (epithelial
cell adhesion molecule, epithelial origin) and EVFAPα (fibroblast activation protein α, mesenchymal origin). The
EV-MAP provided recovery >80% with a specificity of 99 ± 1%
based
on exosomal mRNA (exo-mRNA) and real time–droplet digital polymerase
chain reaction results. When selected from the plasma of healthy donors
and breast cancer patients, EVs did not differ in size or total RNA
mass for both markers. On average, 0.5 mL of plasma from breast cancer
patients yielded ∼2.25 ng of total RNA for both EVEpCAM and EVFAPα, while in the case of cancer-free individuals,
it yielded 0.8 and 1.25 ng of total RNA from EVEpCAM and
EVFAPα, respectively. To assess the potential of
these two EV subpopulations to provide molecular information for prognostication,
we performed the PAM50 test (Prosigna) on exo-mRNA harvested from
each EV subpopulation. Results suggested that EVEpCAM and
EVFAPα exo-mRNA profiling using subsets of the PAM50
genes and a novel algorithm (i.e., exo-PAM50) generated 100% concordance
with the tumor tissue